These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20025499)

  • 1. Generation of novel anti-BTLA monoclonal antibodies for in vivo use and their functional testing at near-physiological conditions.
    Gurka S; Worbs S; Kroczek RA
    Hybridoma (Larchmt); 2009 Dec; 28(6):405-14. PubMed ID: 20025499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of protein on BTLAlow cells and in vivo antibody-mediated down-modulation of BTLA on lymphoid and myeloid cells of C57BL/6 and BALB/c BTLA allelic variants.
    del Rio ML; Kaye J; Rodriguez-Barbosa JI
    Immunobiology; 2010 Jul; 215(7):570-8. PubMed ID: 19837478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus.
    Zhang M; Howard K; Winters A; Steavenson S; Anderson S; Smelt S; Doellgast G; Sheelo C; Stevens J; Kim H; Hamburger A; Sein A; Caughey DJ; Lee F; Hsu H; Siu G; Byrne FR
    Clin Exp Immunol; 2011 Jan; 163(1):77-87. PubMed ID: 21078085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
    Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
    Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
    M'Hidi H; Thibult ML; Chetaille B; Rey F; Bouadallah R; Nicollas R; Olive D; Xerri L
    Am J Clin Pathol; 2009 Oct; 132(4):589-96. PubMed ID: 19762537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.
    Kuncewicz K; Battin C; Sieradzan A; Karczyńska A; Orlikowska M; Wardowska A; Pikuła M; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
    Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
    J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
    Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis.
    Ishida W; Fukuda K; Kajisako M; Sumi T; Matsuda H; Yagita H; Fukushima A
    Graefes Arch Clin Exp Ophthalmol; 2012 Feb; 250(2):289-95. PubMed ID: 21779950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
    Murphy TL; Murphy KM
    Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model.
    Pierer M; Schulz A; Rossol M; Kendzia E; Kyburz D; Haentzschel H; Baerwald C; Wagner U
    J Immunol; 2009 Mar; 182(5):3139-45. PubMed ID: 19234211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
    Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.
    Sedy JR; Gavrieli M; Potter KG; Hurchla MA; Lindsley RC; Hildner K; Scheu S; Pfeffer K; Ware CF; Murphy TL; Murphy KM
    Nat Immunol; 2005 Jan; 6(1):90-8. PubMed ID: 15568026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
    Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
    J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.
    Yu X; Zheng Y; Mao R; Su Z; Zhang J
    Front Immunol; 2019; 10():617. PubMed ID: 30984188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.
    Sakoda Y; Park JJ; Zhao Y; Kuramasu A; Geng D; Liu Y; Davila E; Tamada K
    Blood; 2011 Feb; 117(8):2506-14. PubMed ID: 21220749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting Edge: the BTLA-HVEM regulatory pathway interferes with protective immunity to intestinal Helminth infection.
    Breloer M; Hartmann W; Blankenhaus B; Eschbach ML; Pfeffer K; Jacobs T
    J Immunol; 2015 Feb; 194(4):1413-6. PubMed ID: 25595777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.